TY  - JOUR
AU  - Klein, Eva-Maria
AU  - Tichy, Diana
AU  - Salwender, Hans J
AU  - Mai, Elias K
AU  - Duerig, Jan
AU  - Weisel, Katja C
AU  - Benner, Axel
AU  - Bertsch, Uta
AU  - Akhavanpoor, Mabast
AU  - Besemer, Britta
AU  - Munder, Markus
AU  - Lindemann, Hans-Walter
AU  - Hose, Dirk
AU  - Seckinger, Anja
AU  - Luntz, Steffen
AU  - Jauch, Anna
AU  - Elmaagacli, Ahmet
AU  - Fuhrmann, Stephan
AU  - Brossart, Peter
AU  - Goerner, Martin
AU  - Bernhard, Helga
AU  - Raab, Marc S
AU  - Blau, Igor W
AU  - Haenel, Mathias
AU  - Scheid, Christof
AU  - Goldschmidt, Hartmut
AU  - On Behalf Of The German-Speaking Myeloma Multicenter Group Gmmg
TI  - Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial.
JO  - Cancers
VL  - 13
IS  - 19
SN  - 2072-6694
CY  - Basel
PB  - MDPI
M1  - DKFZ-2021-02258
SP  - 4856
PY  - 2021
AB  - We investigated the prognostic impact of time-dependent serum free light chain ratio (FLCr) normalization in 590 patients with secretory multiple myeloma (MM) during first-line treatment within the German-Speaking Myeloma Multicenter Group MM5 trial. Serum free light chains (sFLC) were assessed by the Freelite test at baseline, after induction, mobilization, autologous blood stem cell transplantation, consolidation and every three months during maintenance or follow up within two years after the start of maintenance. The proportion of patients with a normal or normalized FLCr increased from 3.6
KW  - immune reconstitution (Other)
KW  - multiple myeloma (Other)
KW  - prognostic factors (Other)
KW  - serum free light chain ratio normalization (Other)
KW  - time-dependent analysis (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:34638344
DO  - DOI:10.3390/cancers13194856
UR  - https://inrepo02.dkfz.de/record/177028
ER  -